Suppr超能文献

联合检测凝血因子 XIII 和 D - 二聚体有助于疑似肺栓塞患者的鉴别诊断。

Combined measurement of factor XIII and D-dimer is helpful for differential diagnosis in patients with suspected pulmonary embolism.

作者信息

Tang Ning, Sun Ziyong, Li Dengju, Yang Jun, Yin Shiyu, Guan Qing

机构信息

.

出版信息

Clin Chem Lab Med. 2017 Oct 26;55(12):1948-1953. doi: 10.1515/cclm-2017-0072.

Abstract

BACKGROUND

D-dimer has been used to rule out pulmonary embolism (PE). Based on previous reports of decreased concentrations of coagulation factor XIII (FXIII) in venous thromboembolism, and no change in FXIII concentration in patients with acute cardiovascular disease, we evaluated the benefit of simultaneously measuring D-dimer and FXIII concentrations for diagnosing PE.

METHODS

In this prospective single-center study, we enrolled 209 patients initially suspected of having PE, and measured their D-dimer and FXIII concentrations. Forty-one patients were diagnosed with PE and 168 with other final diagnoses, including acute coronary syndrome (ACS); aortic dissection (AD); spontaneous pneumothorax (SP); other respiratory, heart, digestive and nervous diseases; and uncertain diagnoses.

RESULTS

Patients with PE had significantly higher D-dimer and lower FXIII concentrations than did patients without PE. Combined D-dimer and FXIII measurements provided a higher positive predictive value (76.6%) for PE than single tests, especially in patients with Wells score >4.0 (89.3%). Specifically, patients with AD or ACS showed higher FXIII concentrations and mean platelet volumes than did patients with PE or SP, and patients with PE and AD had higher D-dimer concentrations than did other patients. At the thresholds of 69.0% for FXIII and 1.10 μg/mL for D-dimer, 123/151 patients (81.5%) with serious diseases (PE, AD, ACS and SP) were correctly distinguished.

CONCLUSIONS

Combined measurement of D-dimer and FXIII helps distinguish PE from serious diseases with similar symptoms and appears to relate to increased FXIII release from active platelets in cardiovascular disease.

摘要

背景

D - 二聚体已被用于排除肺栓塞(PE)。基于先前关于静脉血栓栓塞中凝血因子 XIII(FXIII)浓度降低的报道,以及急性心血管疾病患者 FXIII 浓度无变化的情况,我们评估了同时检测 D - 二聚体和 FXIII 浓度对诊断 PE 的益处。

方法

在这项前瞻性单中心研究中,我们纳入了 209 例最初怀疑患有 PE 的患者,并检测了他们的 D - 二聚体和 FXIII 浓度。41 例患者被诊断为 PE,168 例患者有其他最终诊断,包括急性冠状动脉综合征(ACS);主动脉夹层(AD);自发性气胸(SP);其他呼吸、心脏、消化和神经系统疾病;以及诊断不明确的情况。

结果

与无 PE 的患者相比,PE 患者的 D - 二聚体浓度显著更高,FXIII 浓度更低。联合检测 D - 二聚体和 FXIII 对 PE 的阳性预测值(76.6%)高于单项检测,尤其是在 Wells 评分>4.0 的患者中(89.3%)。具体而言,AD 或 ACS 患者的 FXIII 浓度和平均血小板体积高于 PE 或 SP 患者,PE 和 AD 患者的 D - 二聚体浓度高于其他患者。在 FXIII 为 69.0%、D - 二聚体为 1.10 μg/mL 的阈值下,151 例患有严重疾病(PE、AD、ACS 和 SP)的患者中有 123 例(81.5%)被正确区分。

结论

联合检测 D - 二聚体和 FXIII 有助于将 PE 与具有相似症状的严重疾病区分开来,并且似乎与心血管疾病中活化血小板释放 FXIII 增加有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验